Aduro Biotech Awarded East Bay Innovation Award for its Contributions in Life Sciences and the San Francisco East Bay Commun...
March 10 2017 - 9:00AM
Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with
three distinct immunotherapy technologies, announced today the
receipt of the East Bay Economic Development Alliance’s (East Bay
EDA) East Bay Innovation Award for its innovation within the life
science industry and unique contributions to the East Bay’s
prosperity and culture of innovation.
“We are honored to have been recognized by the East Bay EDA for
our innovative approach to the treatment of cancer and for our
efforts to support and nurture the continued prosperity and rich
culture that makes the East Bay what it is today,” stated Stephen
Isaacs, chairman, president and chief executive officer of Aduro.
“It is the diversity of our community—the people, the academic
institutions, and businesses—that support us in our mission to
bring innovative new therapies to individuals battling
cancer. We are grateful to be in the position to make a
positive difference in the lives of others, within the East Bay and
beyond.”
Founded in Berkeley in 2008 and housed in an 110,853-square foot
building with state-of-the art research facilities, Aduro is proud
to support the local community in a variety of ways. The
company seeks to spark a lasting interest in science through its
participation with the Institute for Science, Technology,
Engineering, and Mathematics (STEM) Education program at California
University, East Bay, as well as help create industry awareness and
employment opportunities in under-represented communities through
an internship program conducted in partnership with local community
colleges. Additionally, the company maintains a close
relationship with local academic institutions, including the
University of California at Berkeley through a research
collaboration relating to their Immunotherapeutics and Vaccine
Research Initiative (IVRI), an initiative focused on identifying
and advancing new treatment options and preventive modalities for
cancer, infectious disease and autoimmune disease.
A corporate video about Aduro is available at
http://www.aduro.com/media/corporate-video/.
About the East Bay Economic Development Alliance (East
Bay EDA) The East Bay Economic Development Alliance is a
public-private partnership founded in 1990, and serves the Bay
Area’s East Bay region (Alameda and Contra Costa Counties). East
Bay EDA’s mission is to be the regional voice and networking
resource for strengthening the economy, building the workforce and
enhancing the quality of life in the East Bay. For more
information on East Bay EDA, please go to: www.EastBayEDA.org
About Aduro Aduro Biotech, Inc. is an
immunotherapy company focused on the discovery, development and
commercialization of therapies that transform the treatment of
challenging diseases. Aduro's technology platforms, which are
designed to harness the body's natural immune system, are being
investigated in cancer indications and have the potential to expand
into autoimmune and infectious diseases. Aduro's LADD technology
platform is based on proprietary attenuated strains of Listeria
that have been engineered to express tumor-associated antigens to
induce specific and targeted immune responses. This platform is
being developed as a treatment for multiple indications, including
mesothelioma, ovarian, lung and prostate cancers. Additionally, a
personalized form of LADD, or pLADD, is being developed utilizing
tumor neoantigens that are specific to an individual patient’s
tumor. Aduro's STING Pathway Activator platform is designed to
activate the STING receptor in immune cells, resulting in a potent
tumor-specific immune response. ADU-S100 is the first STING Pathway
Activator compound to enter the clinic and is currently being
evaluated in a Phase 1 study in patients with cutaneously
accessible metastatic solid tumors or lymphomas. Aduro’s B-select
monoclonal antibody platform includes a number of immune modulating
assets in research and preclinical development. Aduro is
collaborating with leading global pharmaceutical companies to
expand its products and technology platforms. For more information,
please visit www.aduro.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include
statements regarding our intentions or current expectations
concerning, among other things, our technology platforms, plans,
and the potential for eventual regulatory approval of our product
candidates. In some cases, you can identify these statements by
forward-looking words such as “may,” “will,” “continue,”
“anticipate,” “intend,” “could,” “project,” “seek,” “potential,”
“expect” or the negative or plural of these words or similar
expressions. Forward-looking statements are not guarantees of
future performance and are subject to risks and uncertainties that
could cause actual results and events to differ materially from
those anticipated, including, but not limited to, our history of
net operating losses and uncertainty regarding our ability to
achieve profitability, our ability to develop and commercialize our
product candidates, our ability to use and expand our technology
platforms to build a pipeline of product candidates, our ability to
obtain and maintain regulatory approval of our product candidates,
our ability to operate in a competitive industry and compete
successfully against competitors that have greater resources than
we do, our reliance on third parties, and our ability to obtain and
adequately protect intellectual property rights for our product
candidates. We discuss many of these risks in greater detail
under the heading “Risk Factors” contained in our annual report on
Form 10-K for the year ended December 31, 2016, which is on file
with the Securities and Exchange Commission. Any forward-looking
statements that we make in this press release speak only as of the
date of this press release. We assume no obligation to update our
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
Contact:
Sylvia Wheeler
SVP, Corporate Affairs
510 809 9264
Media Contact:
Susan Lehner
510 809 2137
press@aduro.com
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Apr 2023 to Apr 2024